QID 375467

Date Published: 2021-04-20

QID 375467: Node.js Multiple Vulnerabilities

Node.js is an open-source, cross-platform, JavaScript runtime environment that executes JavaScript code outside of a web browser.

CVE-2021-22883: HTTP2 unknown Protocol cause Denial of Service by resource exhaustion
CVE-2021-22884: Affected Node.js versions are vulnerable to a DNS rebinding attack when the whitelist includes localhost6.
CVE-2021-23840: Vulnerability in OpenSSL which may be exploited through Node.js
Affected Versions:
Prior to Versions 10.24.0 on the 10.x release line
Prior to Versions 12.21.0 on the 12.x release line
Prior to Versions 14.16.0 on the 14.x release line
Prior to Versions 15.10.0 on the 15.x release line

QID Detection Logic:(Unauthenticated)
This QID checks for server banner to detect the vulnerable version of node.js

Successful exploitation could compromise Confidentiality, Integrity and Availability

CVSS V3 rated as High - 7.5 severity.

CVSS V2 rated as Medium - 5.1 severity.

Solution

Customers are advised to download Node.js v10.24.0 (LTS), Node.js v12.21.0 (LTS), Node.js v14.16.0 (LTS), Node.js v15.10.0 (Current)

For more information, visit February 2021 Security Releases

Vendor References

february-2021-security-releases - nodejs.org/en/blog/vulnerability/february-2021-security-releases/

CVEs related to QID 375467

CVE-2021-22884 | CVE-2021-22883 | CVE-2021-23840 |

Software Advisories

Advisory ID	Software	Component	Link
february-2021-security-releases			nodejs.org/en/blog/vulnerability/february-2021-security-releases/

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].